elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q41183693-006E6AC9-1FAA-468E-AE98-A2BDCE877C60
Q41183693-006E6AC9-1FAA-468E-AE98-A2BDCE877C60
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41183693-006E6AC9-1FAA-468E-AE98-A2BDCE877C60
Immunotherapy earns its spot in the ranks of cancer therapy.
P2860
Q41183693-006E6AC9-1FAA-468E-AE98-A2BDCE877C60
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41183693-006E6AC9-1FAA-468E-AE98-A2BDCE877C60
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ca4451b2921e7dd42f4f03dac57f47e8ac72298b
P2860
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells